-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the increasing number of domestic competitors, the competition in the antitumor drug market has become increasingly fierce
.
To this end, domestic companies are accelerating the process of internationalization of blockbuster drugs
.
In this context, cooperation with multinational enterprises has become a trend
.
However, it is worth noting that under this tide of cooperation, many pharmaceutical companies have announced that they will terminate the cooperation
.
For example, last year Shandong Xinhua Medical Equipment Co.
, Ltd.
issued a "Notice on the Termination of Part of the Agency Business of Subsidiary Shanghai Taimei Medical Equipment Co.
, Ltd.
", announcing that it will terminate the cooperation with Johnson & Johnson Medical
.
It is worth noting that Junshi Bio has also disclosed an announcement recently that it has decided to terminate the promotion cooperation with AstraZeneca and withdraw the promotion rights of toripalimab injection agreed in the original agreement
.
It is understood that on February 28, 2021, Junshi Bio and AstraZeneca signed the "Exclusive Promotion Agreement", and the listed company granted AstraZeneca Triprilimab Injection (trade name: Tuoyi) in mainland China.
The exclusive promotion rights for the subsequently approved indications in the field of urological oncology, as well as the exclusive promotion rights for all approved indications in non-core urban areas
.
According to public information, Toripalimab was independently developed by Junshi Bio, and is the first domestic PD-1 drug approved for marketing in China
.
On December 17, 2018, it was approved by the State Food and Drug Administration for marketing.
The first approved indication is for the treatment of unresectable or metastatic melanoma that has failed previous systemic therapy
.
In February this year, toripalimab was officially approved by the NMPA for the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma (NPC) who had previously failed second-line or above systemic therapy.
Treatment with anti-PD-1 monoclonal antibodies
.
According to the recent performance report released by Junshi Bio, the company achieved operating income of 1.
595 billion yuan in 2020, a year-on-year increase of 105.
77%, mainly due to the increase in the sales income of toripalimab injection and the new technology licensing income.
.
It is understood that, in fact, Junshi Bio and AstraZeneca reached a cooperation before, mainly to rely on AstraZeneca's extensive channel network accumulated in China for many years, especially the promotion ability in the county market, to accelerate the promotion of special The commercialization of riprilimab injection in China will help local high-quality innovative drugs to benefit more Chinese patients
.
So why did you suddenly announce the termination of the cooperation this time? In this regard, Junshi Bio said that the termination of the cooperation is mainly due to the gradual maturity of the company's self-built commercialization team, and more indications of toripalimab injection have been successfully included in the new version of the National Medical Insurance Catalogue.
After implementing the company's product commercialization promotion strategy in the next stage of development and actively responding to the future market competition pattern, the company decided to sign the "Exclusive Promotion Agreement Termination Agreement" with AstraZeneca Pharmaceuticals
.
According to the analysis, most pharmaceutical companies terminate their business in order to reduce the loss of profits
.
At present, many pharmaceutical companies are actively expanding their industrial structure and seeking a variety of cooperation methods to increase their industrial competitiveness
.
In this context, there will be many companies that announce the termination of cooperation in the future
.
.
To this end, domestic companies are accelerating the process of internationalization of blockbuster drugs
.
In this context, cooperation with multinational enterprises has become a trend
.
However, it is worth noting that under this tide of cooperation, many pharmaceutical companies have announced that they will terminate the cooperation
.
For example, last year Shandong Xinhua Medical Equipment Co.
, Ltd.
issued a "Notice on the Termination of Part of the Agency Business of Subsidiary Shanghai Taimei Medical Equipment Co.
, Ltd.
", announcing that it will terminate the cooperation with Johnson & Johnson Medical
.
It is worth noting that Junshi Bio has also disclosed an announcement recently that it has decided to terminate the promotion cooperation with AstraZeneca and withdraw the promotion rights of toripalimab injection agreed in the original agreement
.
It is understood that on February 28, 2021, Junshi Bio and AstraZeneca signed the "Exclusive Promotion Agreement", and the listed company granted AstraZeneca Triprilimab Injection (trade name: Tuoyi) in mainland China.
The exclusive promotion rights for the subsequently approved indications in the field of urological oncology, as well as the exclusive promotion rights for all approved indications in non-core urban areas
.
According to public information, Toripalimab was independently developed by Junshi Bio, and is the first domestic PD-1 drug approved for marketing in China
.
On December 17, 2018, it was approved by the State Food and Drug Administration for marketing.
The first approved indication is for the treatment of unresectable or metastatic melanoma that has failed previous systemic therapy
.
In February this year, toripalimab was officially approved by the NMPA for the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma (NPC) who had previously failed second-line or above systemic therapy.
Treatment with anti-PD-1 monoclonal antibodies
.
According to the recent performance report released by Junshi Bio, the company achieved operating income of 1.
595 billion yuan in 2020, a year-on-year increase of 105.
77%, mainly due to the increase in the sales income of toripalimab injection and the new technology licensing income.
.
It is understood that, in fact, Junshi Bio and AstraZeneca reached a cooperation before, mainly to rely on AstraZeneca's extensive channel network accumulated in China for many years, especially the promotion ability in the county market, to accelerate the promotion of special The commercialization of riprilimab injection in China will help local high-quality innovative drugs to benefit more Chinese patients
.
So why did you suddenly announce the termination of the cooperation this time? In this regard, Junshi Bio said that the termination of the cooperation is mainly due to the gradual maturity of the company's self-built commercialization team, and more indications of toripalimab injection have been successfully included in the new version of the National Medical Insurance Catalogue.
After implementing the company's product commercialization promotion strategy in the next stage of development and actively responding to the future market competition pattern, the company decided to sign the "Exclusive Promotion Agreement Termination Agreement" with AstraZeneca Pharmaceuticals
.
According to the analysis, most pharmaceutical companies terminate their business in order to reduce the loss of profits
.
At present, many pharmaceutical companies are actively expanding their industrial structure and seeking a variety of cooperation methods to increase their industrial competitiveness
.
In this context, there will be many companies that announce the termination of cooperation in the future
.
